Antibody–drug conjugate targeting CD30; upon internalization releases MMAE to disrupt microtubules, causing G2/M arrest and apoptosis.
Anti-CD30 monoclonal antibody conjugated to MMAE via a cleavable linker; after CD30 binding and internalization, MMAE is released to inhibit tubulin polymerization, causing G2/M cell-cycle arrest and apoptosis in CD30-positive tumor cells.
NO
INDIRECT
The ADC binds CD30 (not beta-tubulin); after CD30-mediated internalization, MMAE is released and inhibits tubulin polymerization, causing G2/M arrest and apoptosis in CD30-positive cells.
Bispecific antibody targeting DLL3 on neuroendocrine tumor cells and CD47 to block the CD47–SIRPα 'don't‑eat‑me' signal, enhancing macrophage phagocytosis and Fc effector functions.
Bispecific antibody that binds DLL3 on neuroendocrine tumor cells while blocking CD47 to inhibit the CD47–SIRPα 'don't-eat-me' signal, thereby enhancing macrophage-mediated phagocytosis and Fc effector functions (e.g., ADCP/ADCC) against DLL3-positive tumor cells.
YES
DIRECT
The bispecific antibody binds DLL3 on tumor cells and blocks CD47, removing the “don’t‑eat‑me” signal and engaging Fcγ receptors to trigger macrophage-mediated phagocytosis (ADCP) and NK cell ADCC, killing DLL3+ cells.
Bispecific antibody targeting DLL3 on neuroendocrine tumor cells and CD47 to block the CD47–SIRPα 'don't‑eat‑me' signal, enhancing macrophage phagocytosis and Fc effector functions.
Bispecific antibody that binds DLL3 on neuroendocrine tumor cells while blocking CD47 to inhibit the CD47–SIRPα 'don't-eat-me' signal, thereby enhancing macrophage-mediated phagocytosis and Fc effector functions (e.g., ADCP/ADCC) against DLL3-positive tumor cells.
NO
INDIRECT
CD47 is blocked to remove the SIRPα 'don't-eat-me' signal, enhancing ADCP/ADCC against DLL3-positive tumor cells; CD47-expressing cells themselves are not directly targeted for killing.
An individualized mRNA vaccine encoding selected tumor neoantigens; taken up by antigen-presenting cells, translated to neoantigen peptides, and presented on MHC I/II to prime/expand tumor-specific CD8+ and CD4+ T cells.
Individualized mRNA encoding patient-specific tumor neoantigens is taken up by antigen-presenting cells, translated into neoantigen peptides, and presented on MHC I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to recognize and kill neoantigen-bearing tumor cells.
YES
INDIRECT
The vaccine primes/expands neoantigen-specific CD8+ T cells, which recognize the neoantigen peptide–HLA class I complex on tumor cells and kill them via perforin/granzyme and Fas–FasL pathways; the vaccine itself is not cytotoxic.
An individualized mRNA vaccine encoding selected tumor neoantigens; taken up by antigen-presenting cells, translated to neoantigen peptides, and presented on MHC I/II to prime/expand tumor-specific CD8+ and CD4+ T cells.
Individualized mRNA encoding patient-specific tumor neoantigens is taken up by antigen-presenting cells, translated into neoantigen peptides, and presented on MHC I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to recognize and kill neoantigen-bearing tumor cells.
YES
INDIRECT
The vaccine primes neoantigen-specific T cells; CD4+ T cells recognize neoantigen–HLA class II on tumor cells and can lyse them via perforin/granzyme or Fas–FasL pathways (immune-mediated, not drug-delivered).